Controlling the alfalfa weevil in Missouri

"Alfalfa weevil larvae caused moderate to heavy damage in recent years to the first cutting of alfalfa over the entire state. Adults and late developing larvae also caused some heavy damage to regrowth following removal of the first cutting over much of the state. Alfalfa in Missouri is now about 650,000 acres."--First page.Wayne C. Bailey and Ralph E. Munson (Department of Entomology, College of Agriculture)Revised 3/86/6

Controlling the alfalfa weevil--1984

"Alfalfa weevil larvae caused moderate to heavy damage in 1983 to the first cutting of alfalfa over the entire state. Adults and late developing larvae also caused some heavy damage ti regrowth following removal of the first cutting over much of the state. Alfalfa acreage in Missouri is now about 600,000 acres."--First page.Rick L. Brandenburg and Ralph E. Munson (Department of Entomology), and Howell N. Wheaton (Department of Agronomy, College of Agriculture)Revised 1/84/6

Controlling the alfalfa weevil--1983

"Alfalfa weevil larvae caused moderate to heavy damage in 1982 to the first cutting of alfalfa over the entire state. Adults and late developing larvae also caused some heavy damage to regrowth following removal of the first cutting over much of the state. Alfalfa acreage in Missouri is now about 600,000 acres."--First page.Rick L. Brandenburg and Ralph E. Munson (Department of Entomology), and Howell N. Wheaton (Department of Agronomy, College of Agriculture)Revised 3/83/8

Controlling the alfalfa weevil--1985

"Alfalfa weevil larvae caused moderate to heavy damage in 1984 to the first cutting of alfalfa over the entire state. Adults and late developing larvae also caused some heavy damage to regrowth following removal of the first cutting over much of the state. Alfalfa acreage in Missouri is now about 650,000 acres."--First page.Rick L. Brandenburg, Micheal E. Brown and Ralph E. Munson (Department of Entomology), Howell N. Wheaton (Department of Agronomy, College of Agriculture)Revised 1/85/6

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Background Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. Methods RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report on the comparison of short-course versus long-course ADT. Key eligibility criteria were indication for radiotherapy after previous radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to add 6 months of ADT (short-course ADT) or 24 months of ADT (long-course ADT) to radiotherapy, using subcutaneous gonadotrophin-releasing hormone analogue (monthly in the short-course ADT group and 3-monthly in the long-course ADT group), daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as metastasis arising from prostate cancer or death from any cause. The comparison had more than 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 75% to 81% (hazard ratio [HR] 0·72). Standard time-to-event analyses were used. Analyses followed intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov , NCT00541047 . Findings Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60–69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 8·9 years (7·0–10·0), 313 metastasis-free survival events were reported overall (174 in the short-course ADT group and 139 in the long-course ADT group; HR 0·773 [95% CI 0·612–0·975]; p=0·029). 10-year metastasis-free survival was 71·9% (95% CI 67·6–75·7) in the short-course ADT group and 78·1% (74·2–81·5) in the long-course ADT group. Toxicity of grade 3 or higher was reported for 105 (14%) of 753 participants in the short-course ADT group and 142 (19%) of 757 participants in the long-course ADT group (p=0·025), with no treatment-related deaths. Interpretation Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy. Funding Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society

Grain storage management: A guide for keeping your grain in top condition

Grain isn't necessarily "in the bin" after harvest. That is, broken kernels, moisture pockets, insects, storage molds and other problems can set in and take away your hard-earned capital. This publication addresses problems commonly encountered in stored grain as well as the management principles needed to keep dry grain quality high

Controlling the alfalfa weevil, 1981

"Alfalfa weevil larvae caused moderate to heavy damage in 1980 to the first cutting of alfalfa over the entire state. Adults and late developing larvae also caused some heavy damage to regrowth following removal of the first cutting over much of the state. Alfalfa acreage in Missouri is now about 520,000 acres."--First page.James L. Huggans, and Ralph E. Munson (Department of Entomology), Howell N. Wheaton (Department of Agronomy, College of Agriculture)Revised 4/81/7

Controlling the alfalfa weevil, 1980

"Alfalfa weevil larvae caused moderate to heavy damage in 1979 to the first cutting of alfalfa over the entire state. Adults and late developing larvae also caused some heavy damage to regrowth following removal of the first cutting over much of the state. Alfalfa acreage is now about 580,000 acres."--First page.James L. Huggans and Ralph E. Munson (Department of Entomology), Howell N. Wheaton (Department of Agronomy, College of Agriclture)Revised 3/80/7